The estimated Net Worth of Angie You is at least $1.32 Million dollars as of 8 March 2017. Angie You owns over 30,000 units of Oric Pharmaceuticals stock worth over $1,319,195 and over the last 8 years Angie sold ORIC stock worth over $0.
Angie has made over 1 trades of the Oric Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently Angie bought 30,000 units of ORIC stock worth $42,900 on 8 March 2017.
The largest trade Angie's ever made was buying 30,000 units of Oric Pharmaceuticals stock on 8 March 2017 worth over $42,900. On average, Angie trades about 4,286 units every 0 days since 2017. As of 8 March 2017 Angie still owns at least 133,252 units of Oric Pharmaceuticals stock.
You can see the complete history of Angie You stock trades at the bottom of the page.
Angie's mailing address filed with the SEC is C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Oric Pharmaceuticals have traded over $33,873,532 worth of Oric Pharmaceuticals stock and bought 1,422,500 units worth $12,330,600 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon, and Peter Svennilson. On average, Oric Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $996,237. The most recent stock trade was executed by Lori Anne Kunkel on 3 June 2024, trading 20,500 units of ORIC stock currently worth $76,875.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Oric Pharmaceuticals executives and other stock owners filed with the SEC include: